Clinical Trials
Type 2 Diabetes Drug Pipeline Analysis 2024: By Clinical Trial Phase: Late-Stage Products (Phase III and Phase IV), Mid-Stage Products (Phase II), Early-Stage Products (Phase I), Preclinical and Discovery Stage Products; By Drug Class: Biguanides, Sulfonylureas, Meglitinides, Thiazolidinediones (TZDs), Dipeptidyl Peptidase-4 (DPP-4) Inhibitors, Glucagon-like Peptide-1 (GLP-1) Receptor Agonists, Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors, Alpha-Glucosidase Inhibitors; By Product Type; By Treatment Type; Key Players
According to the Centers for Disease Control and Prevention (CDC), 38.6 million individuals, accounting for 11.6% of the entire United States population are affected by diabetes. Out of this, approximately 8.7 million are undiagnosed. Over 95% of people with diabetes have type 2 diabetes.
Moreover, diabetes is a major cause of blindness, kidney failure as well as heart attacks. hence, there has been significant emphasis on developing effective treatment alternatives to manage the condition effectively.
Key Takeaways
- Major companies involved in the type 2 diabetes drugs market include Eli Lilly and Company, Takeda Pharmaceutical Industries, Ltd., Sanofi SA, Novo Nordisk A/S, GSK PLC and others.
- Leading drugs currently under pipeline include Afrezza®, XW-004, and Tirzepatide (LY3298176).
- Regulatory authorities like the United States FDA and EMA play an essential role in the drug pipeline for Type 2 Diabetes as they are offering breakthrough designations and fast-track approvals to various drugs, intended to provide effective treatment alternatives to patients.
Report Coverage
The Type 2 Diabetes Drug Pipeline Report by Expert Market Research gives comprehensive insights into type 2 diabetes drugs currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development. The report includes the analysis of over 100 pipeline drugs and 50+ companies. It will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on type 2 diabetes.
The detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration and ongoing product development activities related to type 2 diabetes are covered.
Type 2 Diabetes Drug Pipeline Outlook
Type 2 diabetes is a chronic condition which affects the glucose synthesis in the body, resulting in high blood sugar levels. It is also known as adult-onset diabetes and is more common than type 1 diabetes. it leads to excessive blood sugar levels in the blood and may cause circulatory, nervous and immune system disorders as well.
Type 2 diabetes is more common in adults. It is caused by insulin resistance and the inability of the pancreas to produce enough insulin to manage blood sugar levels. Common symptoms include increased thirst, frequent urination urge, surge in hunger levels, blurred vision, unintended weight loss, tingling sensation or numbing in feet or hands. Having high-fat accumulation around the abdomen or hips, and obesity are some of the major risk factors for type 2 diabetes. As a result, lifestyle modifications such as frequent exercise, and dietary changes are mostly advised treatments.
Type 2 diabetes drugs can be both oral as well as injectable. Oral drugs include several drug classes like Biguanides (metformin), Sulfonylureas (Glipizide, Glyburide, Glimepiride) and others. GLP-1 receptor agonists (a part of injectable medications) are gaining significant popularity in the market. Several type 2 diabetes drugs in the pipeline are being developed by several prominent healthcare and pharmaceutical companies. There is an influx of investment to combat the rising fatalities associated with type 2 diabetes across the globe.
Type 2 Diabetes – Drug Pipeline Therapeutic Assessment
This section of the report covers the analysis of type 2 diabetes drugs based on various segmentations such as:
By Phase
EMR’s pipeline assessment report covers 50+ drug analyses based on phase.
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
By Drug Class
EMR’s pipeline assessment report covers 50+ drug analyses based on drug classes:
- Biguanides
- Sulfonylureas
- Meglitinides
- Thiazolidinediones (TZDs)
- Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
- Glucagon-like Peptide-1 (GLP-1) Receptor Agonists
- Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors
- Alpha-Glucosidase Inhibitors
By Route of Administration
EMR’s pipeline assessment report covers 50+ drug analyses based on the route of administration.
- Oral
- Parenteral
- Others
Type 2 Diabetes – Pipeline Assessment Segmentation, By Phases
The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase III covers a major share of the total clinical trials conducted, with over 1,514 drugs in the pipeline.
Type 2 Diabetes – Pipeline Assessment Segmentation, By Drug Class
The drug class categories covered under type 2 diabetes pipeline analysis include Biguanides, Sulfonylureas, Meglitinides, Thiazolidinediones (TZDs), Dipeptidyl Peptidase-4 (DPP-4) Inhibitors, Glucagon-like Peptide-1 (GLP-1) Receptor Agonists, Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors, and Alpha-Glucosidase Inhibitors. Glucagon-like Peptide-1 (GLP-1) receptor agonists stimulate insulin release and prevent glucagon release, resulting in satiated feeling. Drugs belonging to this drug class are gaining popularity. Common examples include Liraglutide and Semaglutide among others.
The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials.
Type 2 Diabetes Clinical Trials Assessment – Competitive Dynamics
The EMR report for the type 2 diabetes drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in type 2 diabetes clinical trials:
- Eli Lilly and Company
- Takeda Pharmaceutical Industries, Ltd.
- Sanofi SA
- Novo Nordisk A/S
- GSK PLC
- Others
Type 2 Diabetes – Pipeline Drugs Profile
Afrezza®
Afrezza, designed for type 2 diabetes treatment, is being evaluated in the INHALE-1 trial. The study evaluates its efficacy against insulin analog injections. The drug is particularly being investigated for pediatric patients. Sponsored by Mannkind Corporation, INHALE-1 is a 26-week Primary Treatment Phase, randomized clinical trial.
XW-004
Sciwind Biosciences (Sciwind) is developing XW-004 for type 2 diabetes, obesity as well as nonalcoholic steatohepatitis (NASH). It is a glucagon-like peptide 1 receptor (GLP1R) oral drug developed using polypeptide or recombinant protein preparation platform technology.
Investigational Tirzepatide (LY3298176)
Eli Lilly and Company’s Tirzepatide is under investigation for its efficacy and safety in obese type 2 diabetes participants that are on metformin. Currently in phase 3 of an interventional study, enrolling over 13,000 people, this trial is likely to be completed by June 2025.
Reasons To Buy This Report
The Type 2 Diabetes Drug Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for type 2 diabetes. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities.
| Scope of the Report | Details |
| Drug Pipeline by Clinical Trial Phase |
|
| Route of Administration |
|
| Drug Classes |
|
| Leading Sponsors Covered |
|
| Geographies Covered |
|
Key Questions Answered in the Type 2 Diabetes – Pipeline Assessment Report
- What is the current landscape of type 2 diabetes pipeline drugs?
- How many companies are developing type 2 diabetes drugs?
- How many phase III and phase IV drugs are currently present in type 2 diabetes pipeline drugs?
- Which companies/institutions are leading the type 2 diabetes drug development?
- What is the efficacy and safety profile of type 2 diabetes pipeline drugs?
- What are the opportunities and challenges present in the type 2 diabetes drug pipeline landscape?
- Which company is conducting major trials for type 2 diabetes drugs?
- What are the geographies covered for clinical trials in type 2 diabetes?
- What are emerging trends in type 2 diabetes clinical trials?
Related Reports
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.
1 Preface
1.1 Introduction
1.2 Objectives of the Study
1.3 Research Methodology and Assumptions
2 Executive Summary
3 Overview of Type 2 Diabetes
3.1 Signs and Symptoms
3.2 Causes
3.3 Risk Factors
3.4 Diagnosis
3.5 Treatment
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Type 2 Diabetes: Epidemiology Snapshot
5.1 Type 2 Diabetes Incidence by Key Markets
5.2 Type 2 Diabetes– Patients Seeking Treatment in Key Markets
6 Type 2 Diabetes: Market Dynamics
6.1 Market Drivers and Constraints
6.2 SWOT Analysis
7 Type 2 Diabetes: Key Facts Covered
7.1 Top Countries Contributing to Clinical Trials in Asia-Pacific
7.2 Top Countries Contributing to Clinical Trials in Europe
7.3 Top Countries Contributing to Clinical Trials in North America
7.4 Top Countries Contributing to Clinical Trials in Other Regions
8 Type 2 Diabetes, Drug Pipeline Assessment
8.1 Assessment by Treatment Type
8.2 Assessment by Route of Administration
8.3 Assessment by Drug Class
9 EMR Drug Pipeline Comparative Analysis
9.1 List of Type 2 Diabetes Pipeline Drugs
9.1.1 By Company
9.1.2 By Phase
9.1.3 By Indication
9.1.4 By Trial Status
9.1.5 By Funder Type
9.2 EMR Attribute Scoring Analysis of Pipeline Drugs (Top Drugs)
10 Type 2 Diabetes Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
10.1 Comparative Analysis for Late-Stage Drugs
10.1.1 Study Type
10.1.2 Recruitment Status
10.1.3 Company
10.1.4 Funder Type
10.2 Product Level Analysis*
10.2.1 Empagliflozin
10.2.1.1 Product Description
10.2.1.2 Trial ID
10.2.1.3 Sponsor Name
10.2.1.4 Study Type
10.2.1.5 Drug Class
10.2.1.6 Eligibility Criteria
10.2.1.7 Study Record Dates
10.2.1.7.1 First Submitted
10.2.1.7.2 First Posted
10.2.1.7.3 Last Update Posted
10.2.1.7.4 Last Verified
10.2.1.8 Indication
10.2.1.9 Study Design
10.2.1.10 Recruitment Status
10.2.1.11 Enrollment (Estimated)
10.2.1.12 Location Countries
10.2.1.13 Recent Results
10.2.2 Pioglitazone
10.2.3 Other Drug
11 Type 2 Diabetes Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
11.1 Comparative Analysis for Mid-Stage Drugs
11.1.1 Study Type
11.1.2 Recruitment Status
11.1.3 Company
11.1.4 Funder Type
11.2 Product Level Analysis*
11.2.1 KRP-104
11.2.1.1 Product Description
11.2.1.2 Trial ID
11.2.1.3 Sponsor Name
11.2.1.4 Study Type
11.2.1.5 Drug Class
11.2.1.6 Eligibility Criteria
11.2.1.7 Study Record Dates
11.2.1.7.1 First Submitted
11.2.1.7.2 First Posted
11.2.1.7.3 Last Update Posted
11.2.1.7.4 Last Verified
11.2.1.8 Indication
11.2.1.9 Study Design
11.2.1.10 Recruitment Status
11.2.1.11 Enrollment (Estimated)
11.2.1.12 Location Countries
11.2.1.13 Recent Results
11.2.2 DMMET-01
11.2.3 Other Drugs
12 Type 2 Diabetes Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
12.1 Comparative Analysis for Early-Stage Drugs
12.1.1 Study Type
12.1.2 Recruitment Status
12.1.3 Company
12.1.4 Funder Type
12.2 Product Level Analysis*
12.2.1 D308
12.2.1.1 Product Description
12.2.1.2 Trial ID
12.2.1.3 Sponsor Name
12.2.1.4 Study Type
12.2.1.5 Drug Class
12.2.1.6 Eligibility Criteria
12.2.1.7 Study Record Dates
12.2.1.7.1 First Submitted
12.2.1.7.2 First Posted
12.2.1.7.3 Last Update Posted
12.2.1.7.4 Last Verified
12.2.1.8 Indication
12.2.1.9 Study Design
12.2.1.10 Recruitment Status
12.2.1.11 Enrollment (Estimated)
12.2.1.12 Location Countries
12.2.2 Glipizide
12.2.3 Other Drugs
13 Type 2 Diabetes Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
13.1 Comparative Analysis for Preclinical and Discovery Stage Drugs
13.1.1 Study Type
13.1.2 Recruitment Status
13.1.3 Company
13.1.4 Funder Type
13.2 Product Level Analysis*
13.2.1 Amiloride
13.2.1.1 Product Description
13.2.1.2 Trial ID
13.2.1.3 Sponsor Name
13.2.1.4 Study Type
13.2.1.5 Drug Class
13.2.1.6 Eligibility Criteria
13.2.1.7 Study Record Dates
13.2.1.7.1 First Submitted
13.2.1.7.2 First Posted
13.2.1.7.3 Last Update Posted
13.2.1.7.4 Last Verified
13.2.1.8 Indication
13.2.1.9 Study Design
13.2.1.10 Recruitment Status
13.2.1.11 Enrollment (Estimated)
13.2.1.12 Location Countries
13.2.2 Ertugliflozin
13.2.3 Other Drugs
14 Type 2 Diabetes, Key Drug Pipeline Companies
14.1 Eli Lilly and Company
14.1.1 Company Snapshot
14.1.2 Pipeline Product Portfolio
14.1.3 Financial Analysis
14.1.4 Recent News and Developments
14.2 Takeda Pharmaceutical Industries, Ltd.
14.2.1 Company Snapshot
14.2.2 Pipeline Product Portfolio
14.2.3 Financial Analysis
14.2.4 Recent News and Developments
14.3 Sanofi SA
14.3.1 Company Snapshot
14.3.2 Pipeline Product Portfolio
14.3.3 Financial Analysis
14.3.4 Recent News and Developments
14.4 Novo Nordisk A/S
14.4.1 Company Snapshot
14.4.2 Pipeline Product Portfolio
14.4.3 Financial Analysis
14.4.4 Recent News and Developments
14.5 GSK PLC
14.5.1 Company Snapshot
14.5.2 Pipeline Product Portfolio
14.5.3 Financial Analysis
14.5.4 Recent News and Developments
15 Regulatory Framework for Drug Approval, By Region
16 Terminated or Suspended Pipeline Products
*Complete list of drugs covered will be provided in the report.
The EMR team aims to provide comprehensive coverage of the Top Drugs for each Phase, considering factors such as the company's financial standing, geographic presence, and market position to ensure thorough analysis in this section.
Purchase Options
Call us
Purchase Full Report
Datasheet
$1999
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$2499
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$3499
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$4499
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER